Historically, γBB was discovered because it is an approximate endogenous biosynthetic intermediate for the synthesis of L-carnitine in mammals, and it is a multi-step pathway to produce L-carnitine from lysine. Mice fed with γBB can produce TMA and TMAO and accelerate atherosclerosis, but only in the presence of intestinal microbes. In the past, in the process of oral L-carnitine metabolism of omnivores and vegetarians, gut microbial formation and catabolism of γBB, human symbiosis that can use γBB as a nutrient, and the relationship between this metabolite and the metabolite TMAO pathway and CVD Not yet explored. Therefore, it is of great significance to improve the understanding of oral L-carnitine metabolism in mammals and the potential participation of intestinal microbe-dependent processes.
Based on this, Professor Stanley L. Hazen, Dean of the Department of Cellular and Molecular Medicine at Cleveland Hospital, Ohio, led the team to determine whether γBB is the main product of dietary L-carnitine catabolism in the human body’s gut microbial catabolism, as well as chronic dietary patterns (e.g., omnivorous and omnivorous diets). (Vegetarian food) and the relationship between L-carnitine exposure to γBB metabolism in the human body have been deeply explored. This work was published in "The Journal of Clinal Investigation" with the title "L-Carnitine in omnivorous diets induces an atherogenic gut microbial pathway in humans". In the magazine.